Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.9650 (1.6%) ($6.9650 - $6.9900) on Wed. Sep. 14, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.68% (three month average) | RSI | 48 | Latest Price | $6.9650(1.6%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.7% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) SPLV(76%) USO(-29%) UUP(-81%) SDY(79%) SHY(70%) | Factors Impacting TGTX price | TGTX will decline at least -3.34% in a week (0% probabilities). EEM(75%) IDRV(77%) BNDX(57%) KWEB(81%) JNK(87%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.34% (StdDev 6.68%) | Hourly BBV | -0.5 () | Intraday Trend | 0% | | | |
|
Resistance Level | $6.99 | 5 Day Moving Average | $7.12(-2.18%) | 10 Day Moving Average | $6.95(0.22%) | 20 Day Moving Average | $6.99(-0.36%) | To recent high | -17.3% | To recent low | 86.5% | Market Cap | $882m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |